Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ferrara F.
- Geissler K.
- Mehta P.
- Venditti A.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 2234-943X, 2234-943X
- Tipo:
- Article
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,291 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Frontiers in Oncology FRONTIERS MEDIA SA
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- antineoplastic agent; apvo436; azacitidine; azd5991; bleximenib; CD135 antigen; crelosidenib; crenolanib; cusatuzumab; decitabine; emavusertib; emirodatamab; enasidenib; entinostat; entospletinib; eprenetapopt; evorpacept; ff 10101; flotetuzumab; gilteritinib; h3b 8800; hypomethylating agent; iadademstat; ipilimumab; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; ivosidenib; jnj 74856665; lemzoparlimab; luxeptinib; milademetan; nivolumab; olaparib; pembrolizumab; pevonedistat; pinometostat; pivekimab sunirine; ponatinib; protein p53; prt543; relatlimab; revumenib; s55746; s64315; s65487; sabatolimab; siremadlin; spartalizumab; tamibarotene; tapotoclax; tuspetinib; unclassified drug; uproleselan; vadastuximab; venetoclax; vibecotamab; vixtimotamab; ziftomenib; acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; Article; cancer chemotherapy; cancer incidence; cancer prognosis; Charlson Comorbidity Index; clinical assessment; cognition; cognitive defect; c
Cita
Ferrara F,Geissler K,Mehta P,MONTESINOS P,Venditti A. Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel. Front. Oncol. 2025. 15. 1642472. IF:3,400. (2).
Portal de investigación